Meibomian Gland Dysfunction Pipeline Overview: 4+ Emerging Therapies Targeting a Leading Cause of Dry Eye Disease | DelveInsight

Meibomian Gland Dysfunction (MGD)-a chronic and progressive condition affecting the eyelid's oil-producing glands-is the leading cause of evaporative dry eye disease (DED), impacting millions globally. Characterized by altered gland function, reduced lipid secretion, and increased tear film instability, MGD can significantly compromise ocular surface health and visual comfort. Despite its high prevalence, current treatment options remain limited, primarily focused on symptomatic relief through lubricants, warm compresses, or mechanical gland expression.

However, the therapeutic pipeline for MGD is expanding, driven by a growing understanding of glandular pathophysiology and inflammation. Biotech and pharmaceutical companies are developing targeted approaches that go beyond symptomatic management, focusing instead on restoring meibomian gland function, controlling inflammation, and enhancing tear film stability. Innovative candidates include anti-inflammatory agents, androgen modulators, regenerative therapies, and devices enhancing glandular secretion.

Companies such as Azura Ophthalmics, Novaliq, Bausch + Lomb, Oyster Point Pharma, and i-Med Pharma are advancing novel topical drugs, combination therapies, and device-based solutions tailored to the unique pathogenesis of MGD. These innovations aim to normalize meibum quality, unblock gland ducts, and slow disease progression.

DelveInsight's "Meibomian Gland Dysfunction - Pipeline Insight, 2025" offers a comprehensive evaluation of clinical and early-stage assets targeting this underdiagnosed condition. The report profiles a diverse range of therapies under development, highlights key advances in drug delivery systems for the ocular surface, and outlines emerging trial designs and regulatory updates shaping the competitive landscape.

As unmet needs persist for long-term and disease-modifying treatments, the evolving MGD pipeline presents a promising opportunity to redefine management strategies and improve quality of life for patients affected by this widespread ocular surface disorder.

Interested in learning more about the current treatment landscape and the key drivers shaping the meibomian gland dysfunction pipeline? Click here: https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Meibomian Gland Dysfunction Pipeline Report
• DelveInsight's meibomian gland dysfunction pipeline analysis depicts a strong space with 4+ active players working to develop 4+ pipeline drugs for meibomian gland dysfunction treatment.
• The leading meibomian gland dysfunction companies include Azura Ophthalmics, Avania, Cloudbreak Therapeutics LLC, Tear Film Innovations Inc., AxeroVision Inc., ORA Inc., Hovione Scientia Limited, Allergan, TearScience Inc., Alcon Research, Novoxel Ltd., and others are evaluating their lead assets to improve the meibomian gland dysfunction treatment landscape.
• Key meibomian gland dysfunction pipeline therapies in various stages of development include AZR-MD-001, Sirolimus ophthalmic, and others.
• In May 2025, Alcon (SIX/NYSE: ALC) announced FDA approval of TRYPTYR® (acoltremon ophthalmic solution) 0.003% for treating signs and symptoms of Dry Eye Disease. TRYPTYR is a first-in-class TRPM8 receptor agonist that boosts natural tear production by stimulating corneal nerves.
• In April 2025, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that the FDA issued a Complete Response Letter for the resubmitted New Drug Application of reproxalap, their investigational treatment for dry eye disease.
• In February 2025, Cambium Bio announced that the FDA approved the protocol for the phase III clinical trials of elate ocular for treating moderate to severe dry eye disease.
• In November 2024, Novoxel Inc. announced FDA clearance of the Tixel i for sale in the USA, approved for treating Evaporative Dry Eye caused by Meibomian Gland Dysfunction (MGD) using localized heat and pressure.

Request a sample and discover the recent breakthroughs happening in the meibomian gland dysfunction pipeline landscape at https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Meibomian Gland Dysfunction Overview
Meibomian Gland Dysfunction (MGD) is a chronic and highly prevalent condition that affects the meibomian glands located along the eyelid margins. These glands are responsible for secreting lipids that form the outer layer of the tear film, preventing rapid tear evaporation. In MGD, gland obstruction or altered lipid production leads to tear film instability, evaporative dry eye, and ocular surface inflammation. The condition is a leading cause of dry eye disease globally and is particularly common in aging populations and those exposed to environmental stressors like screen use and air conditioning.

Despite its widespread impact, MGD remains underdiagnosed and undertreated. Current management includes warm compresses, lid hygiene, antibiotics, and device-based therapies such as thermal pulsation and intense pulsed light (IPL). However, the response is often variable, and no FDA-approved pharmacologic treatments specifically target MGD. This has spurred growing interest in research and development focused on anti-inflammatory agents, novel delivery systems, and innovative devices aimed at restoring gland function and improving long-term outcomes.

Find out more about meibomian gland dysfunction medication at https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Meibomian Gland Dysfunction Treatment Analysis: Drug Profile
AZR-MD-001: Azura Ophthalmics
AZR-MD-001 is Azura's lead investigational ophthalmic ointment containing selenium sulfide (SeS2), applied to the lower eyelid's meibomian glands and transferred to the upper glands through blinking. It works via a multi-modal approach to treat Meibomian Gland Dysfunction (MGD) by breaking down abnormal keratin bonds to clear blockages, reducing keratin production to prevent new blockages, and improving both the quality and quantity of meibum. The drug is currently in Phase III trials assessing its safety, efficacy, and tolerability in patients with MGD.

Learn more about the novel and emerging meibomian gland dysfunction pipeline therapies at https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Meibomian Gland Dysfunction Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Meibomian Gland Dysfunction Pipeline Report
• Coverage: Global
• Key Meibomian Gland Dysfunction Companies: Azura Ophthalmics, Avania, Cloudbreak Therapeutics LLC, Tear Film Innovations Inc., AxeroVision Inc., ORA Inc., Hovione Scientia Limited, Allergan, TearScience Inc., Alcon Research, Novoxel Ltd., and others.
• Key Meibomian Gland Dysfunction Pipeline Therapies: AZR-MD-001, Sirolimus ophthalmic, and others.

Dive deep into rich insights for drugs used for meibomian gland dysfunction treatment, visit: https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Meibomian Gland Dysfunction Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Meibomian Gland Dysfunction Pipeline Therapeutics
6. Meibomian Gland Dysfunction Pipeline: Late-Stage Products (Phase III)
7. Meibomian Gland Dysfunction Pipeline: Mid-Stage Products (Phase II)
8. Meibomian Gland Dysfunction Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.